Dr. Ryan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
550 1st Ave
New York, NY 10016Phone+1 212-212-7300
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2003- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2001
- NYU Grossman School of MedicineResidency, Internal Medicine, 1996 - 1999
- New York University School of MedicineClass of 1996
Certifications & Licensure
NY State Medical License 1999 - 2026- American Board of Internal Medicine Medical Oncology
- American Board of Preventive Medicine Clinical Informatics
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Chemoradiation With Oxaliplatin and Fluorouracil (5FU) for Locally Advanced Pancreatic Cancer Start of enrollment: 2004 Jun 01
- Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Start of enrollment: 2005 Jul 01
- Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Start of enrollment: 2011 Apr 07
Publications & Presentations
PubMed
- 14 citationsDocetaxel, Oxaliplatin, and 5‐Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long‐Term Follo...Ari Rosenberg, Alfred Rademaker, Howard S. Hochster, Theresa Ryan, Thomas A. Hensing
The Oncologist. 2019-08-01 - 2 citationsCan we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiationSalvatore Amodeo, Antonio Masi, Marcovalerio Melis, Theresa Ryan, Howard S. Hochster
Journal of Gastrointestinal Oncology. 2018-10-01 - 20 citationsMulticenter, randomized, double‐blind phase 2 trial of FOLFIRI with regorafenib or placebo as second‐line therapy for metastatic colorectal cancerHanna K. Sanoff, Richard M. Goldberg, Anastasia Ivanova, Seamus O'Reilly, Samer S. Kasbari
Cancer. 2018-08-01
Press Mentions
Bad Fat, Misbehaving Kidneys May Share Common OffenderSeptember 16th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
